$ME->Wakeup('2021-02-15 00:00:00');
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I like Clay's videos and am thankful they are here. Far better than a lot of the meaningless banter that I need to sort through. Props to you Clay!
DC is #1 location to search RLFTF on Google
https://trends.google.com/trends/explore?q=RLFTF&geo=US
So there's a lot of people there would would be the first to know if we were going to have a therapeutic soon (Or maybe everyone here is from Washington DC? :)
VIP was first discovered in 1970 by Sami Said, MD
SAMIVIR™
https://uspto.report/TM/90087709
It wasn't some blogger, Dr Javitt said this
NeuroRX applies for US Trademark for RLF-100 name
RLF AG filing using the Madrid protocol can be challenging, much easier to have NeuroRx file. They did on 08/13
https://uspto.report/TM/90110838
Great link, thank you. Its easier to understand and has better freehand artwork :)
Want to know more about RLF-100?
DC insiders making shell companies to use as a veil so they can purchase RLFTF without exposing their insider status since the shell did it and theyd just get a K1 from the shell? You think that happens?...
US Regions google searches for RLFTF
https://trends.google.com/trends/explore?q=RLFTF&geo=US
Thats really strange that the smallest area is #1. Anything people there might have information on that others dont?
I cant seem to put my finger on it...
JTORENCE - 22:50 Minute mark of Dr Yo interview Dr Javitt says (sic)"More than 100 ppl treated intravenously, zero adverse affects besides diarrhea"
Over 100 people have it, he just presented to his graduating class at Princeton. You think he would know how the study is going before presenting to his Alma Mater class?
Wish you were a Princeton '78 Alum and watched today? Easy fix, it went like this but better -- watch this again and the many statements makes.
A) They’ve been designated fast track status and compassionate use by the FDA, not many Covid treatments have this FDA status.
B) The FDA has just approved a 3rd clinical trial, this one for an inhaler to treat Covid, this potential has to register for any investor. What an excellent delivery method for an outpatient treatment. Furthermore, they didn’t approve this trial on air, they obviously had some science and data to approve this based on feedback from other clinical trials; https://clinicaltrials.gov/ct2/results?cond=&term=aviptadil&cntry=&state=&city=&dist=
C) Have you looked at who is on their data safety monitoring committee? The Dean of Epidemiology at Johns Hopkins, a Congressman, and a former WH appointed National Science Director. You can’t truly believe these people would be involved in a pump and dump? On top of that, based on initial observations the primary endpoints of one of their trials was changed (and as opposite of Remdisivir, it was made to make the outcome even more difficult to prove efficacy); these individuals recommended changing endpoints from mortality at 28 days to free of respiratory failure at 7-10 days, that’s pretty incredible. I trust this DSMC.
Rita Colwell https://en.wikipedia.org/wiki/Rita_R._Colwell
Congressman Andy Harris https://en.wikipedia.org/wiki/Andy_Harris_(politician))
https://www.jhsph.edu/faculty/directory/profile/658/alfred-sommer Dean Epidemiology at Johns Hopkins
You think they're in on the pump and dump? DD is your friend. Sure, a lot of lucky idiots stumbled into this one, but also smart money finding it too.
D) Dr Javitt who leads their clinical trials is a heavyweight with a ton of big pharma experience and a wealth of government connections. Dr. Ram (Chairman) is a leading analyst in the small cap biotech space. All of these pieces weren’t put in place to destroy lifelong built reputations for a pump and dump.
E) A terribly mismanaged company named Cytodyn also with a treatment who stumbles left and right has averaged a market cap that is over triple Relief’s in the last 3 months. Why can’t they get there? Cytodyn topped out at over $5B, Relief Therapeutics has better connections, better management, and possibly a better product.
F) Oswego Institute reported their study that showed Aviptadil blocks replication of Covid in the lungs (which is what causes death) while also calming cytokines, nothing else has reported anything else even close. https://relieftherapeutics.com/fda-grants-inhaled-use-ind-for-rlf-100-aviptadil-to-treat-patients-with-moderate-and-severe-covid-19-aiming-to-prevent-progression-to-respiratory-failure/
You can review my comments and try to debunk any of them, but it is all iron clad for now. The clinical trials are happening, positive anecdotal evidence is coming out, legitimate indviduals with serious pharma backgrounds are involved, and few treatments look this promising.
I also understand the initial reaction to look at share structure and respond with P&D, but their drug can be worth billions annually. An inhaled version of a treatment to cure lungs after Covid infection, currently under 3 trials, supported by a large swath of people with excellent reputations, the risk/reward is there IMO and I’ll buy into any selling at this juncture.
Good luck, and I do appreciate any comments and disclosures, I'm obviously long. I’d recommend really diving in here and doing some DD on your own. Avoid the P&D forums and go find the actual information itself, it's out there and it is impressive. It’s easy to have a slanted opinion when you’ve missed out on massive gains, still healthy up
RLFTF separates itself from other FastTracked Therapeutics
A) They’ve been designated fast track status and compassionate use by the FDA, not many Covid treatments have this FDA status but they are the farthest along
B) The FDA has just approved a 3rd clinical trial, this one for an inhaler to treat Covid, this potential has to register for any investor. What an excellent delivery method for an outpatient treatment. Furthermore, they didn’t approve this trial on air, they obviously had some science and data to approve this based on feedback from other clinical trials; https://clinicaltrials.gov/ct2/results?cond=&term=aviptadil&cntry=&state=&city=&dist=
C) Have you looked at who is on their data safety monitoring committee? The Dean of Epidemiology at Johns Hopkins, a Congressman, and a former WH appointed National Science Director. You can’t truly believe these people would be involved in a pump and dump? On top of that, based on initial observations the primary endpoints of one of their trials was changed (and as opposite of Remdisivir, it was made to make the outcome even more difficult to prove efficacy); these individuals recommended changing endpoints from mortality at 28 days to free of respiratory failure at 7-10 days, that’s pretty incredible. I trust this DSMC.
Rita Colwell https://en.wikipedia.org/wiki/Rita_R._Colwell
Congressman Andy Harris https://en.wikipedia.org/wiki/Andy_Harris_(politician))
https://www.jhsph.edu/faculty/directory/profile/658/alfred-sommer Dean Epidemiology at Johns Hopkins
You think they're in on the pump and dump? DD is your friend. Sure, a lot of lucky idiots stumbled into this one, but also smart money finding it too.
D) Dr Javitt who leads their clinical trials and is Reliefs vice chairman is a heavyweight with a ton of big pharma experience and a wealth of government connections. He is well respected for good reason, read his bio.
All of these pieces weren’t put in place to destroy lifelong built reputations for a pump and dump.
E) A terribly mismanaged company named Cytodyn also with a treatment who stumbles left and right has averaged a market cap that is over triple Relief’s in the last 3 months. Why can’t they get there? Cytodyn topped out at over $5B, Relief Therapeutics has better connections, better management, and possibly a better product.
F) Oswego Institute reported their study that showed Aviptadil blocks replication of Covid in the lungs (which is what causes death) while also calming cytokines, nothing else has reported anything else even close. https://relieftherapeutics.com/fda-grants-inhaled-use-ind-for-rlf-100-aviptadil-to-treat-patients-with-moderate-and-severe-covid-19-aiming-to-prevent-progression-to-respiratory-failure/
You can review my comments and try to debunk any of them, but it is all iron clad for now. The clinical trials are happening, positive anecdotal evidence is coming out, legitimate indviduals with serious pharma backgrounds are involved, and few treatments look this promising.
I also understand the initial reaction to look at share structure and respond with P&D, but their drug can be worth billions annually. An inhaled version of a treatment to cure lungs after Covid infection, currently under 3 trials, supported by a large swath of people with excellent reputations, the risk/reward is there IMO and I’ll buy into any selling at this juncture.
Good luck, and I do appreciate any comments and disclosures, I'm obviously long. I’d recommend really diving in here and doing some DD on your own. Avoid the P&D forums and go find the actual information itself, it's out there and it is impressive. It’s easy to have a slanted opinion when you’ve missed out on massive gains, still healthy up
He presented to HIS class at HIS Alma Matta...
It surely went well and many are surely wanting to get a piece of the pie
Yale Alum certainly will want to get in on this. Certainly they will be introduced to Dr Javitt's bio at some point and then I'd expect the presentation to be even better than the Dr Yo interview. If this is the first time they are hearing about it, many surely will want in at open. My guess is some good movement on SIX before the US and gap up on US opening with upwards substantial movement. Then maybe some pull pack until we have another PR. My guess is that sub 0.50 is long gone
Any Princeton '78 alum? Surely we all want to see the private zoom meeting but will have to wait until posted after. Any guesses as to how long after it will be posted in their archive? Just was trying to plan my day and see if I should be looking at a new boat :)
Available Outstanding Shares:
Total - 2,302,499,272
Authorized - 1,114,749,636
Conditional - 1,041,749,636
Exactly
I'd like to think of Lester Holt indicating that Relief Therapeutics has just announced a partnership with Nephron Pharmaceuticals for manufacturing at their Nephron Sterile Compounding facility and that it has also announced they have partnered with Mckesson for distribution of Relief's breakthrough COVID-19 therapeutic in response to the FDA asking for such a plan.
That's just my thought though, what do I know ... (cough)
Listen closely to what Trump said during 08/14 briefing about Mckesson.
"We have a great general who’s in charge, that’s what he does is he distributes things, usually it’s people and weapons, tanks, but in this case it’s a vaccine or therapeutic as it may be."
https://www.rev.com/blog/transcripts/donald-trump-white-house-press-conference-transcript-august-14
Anyone know of any pharma company planning on announcing anything with regards to distribution? The 08/12 interview with Dr Javitt, he says they "are going to announce a partnership with a company that can get a drug to any hospital overnight".
Maybe I should have added RLFTF to my portfolio? :)
j/k I am in so deep they literally would send the jet just to get me to the annual shareholders meeting
Available Outstanding Shares:
Total - 2,302,499,272
Authorized - 1,114,749,636
Conditional - 1,041,749,636
You should use these numbers when figure out what percentage of available outstanding shares you own vs how many are out there in total
*Spoiler Alert*
Its about a billion, not 2 billion
This is not coincidence:
- Trump now mentions therapeutics every time now when asked about vaccines
- Trump indicated today (08/14) the US has partnered with Mckesson for distribution of Vaccines
- Trump keeps indicating we will have some new very very soon on Theraputics which he "likes better"
- Dr Javitt (NeuroRx CEO) indicated on 08/12 livestream with Dr. Yo that they will be announcing a partnership with a distributor who can distribute to any hospital within 24 hours
*- Noone else besides Mckesson could do this IMO
- Dr Javitt also indicated on the same livestream that they will be reporting "next week" results from the first 21 which all look good
This along with the mild/moderate inhaled study being announced, the announcement partnership with a aerosol pharma manufacturer, the scheduled Sunday Princeton alumni interview with Dr. Javitt ALL seem to make me have confidence in this rising. Sell your shares, I will will hang onto mine
## DISCLOSURE ##
I own a tremendous amount of RLFTF that I bought at a very low price :)